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 MicroRNA-mediated gene regulation is an important component of cell biology, 
involved in nearly all cellular processes. MicroRNAs are ~22 nucleotide non-coding 
RNAs that recognize complimentary mRNA targets and prevent them from being 
translated. To achieve this, the microRNA (miRNA) must be accompanied by one or 
more proteins known collectively as the RNA-induced silencing complex (RISC). The 
central component of the RISC is one of four Argonaute proteins. One of these proteins, 
Ago2, has endonuclease activity. Guided by a miRNA, Ago2 can directly cleave the 
mRNA target without assistance from any other RISC members. MiRNA repression is 
reduced upon stress when all Argonaute members, including Ago2, are modified by 
poly(ADP-ribose). Similar reduction in microRNA repression occurs upon knockdown of 
poly(ADP-ribose) degrading enzyme PARG or, conversely, by overexpression of specific 
poly(ADP-ribose) polymerases including PARP-12 and PARP-13. Moreover, Ago2 has 
been shown to be associated with PARP-5a, PARP-12 and PARP-13 by co-
immunoprecipitation and co-localization at stress granules. 
The aim of this project is to use recombinant proteins to ADP-ribosylate Ago2 in 
vitro to determine whether and how this modification affects Ago2-mediated RNA 
activity and if the modification can be reversed by PARG or another poly(ADP-ribose) 
hydrolase, ARH3. This thesis will describe the purification of ARH3 and the catalyctic 
domain of PARP-12 from E. coli. ARH3 is demonstrated to be an active glycohdrolase 
and PARP-12cat is demonstrated to be a mono(ADP-ribose) tranferase. Our results 
suggest that Ago2 can be mono(ADP-ribosyl)ated by PARP-12cat and may be poly(ADP-
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ribosyl)ated by PARP-5a in vitro. Finally, an Ago2 cleavage assay has been recapitulated 
and optimized. 
 The work in this thesis project has established the necessary tools to test 
the hypothesis that mono(ADP-ribosyl)ation or poly(ADP-ribosyl)ation will repress 
Ago2 activity and whether its activity can be recovered with PARG or ARH3. Other 




 Dr. Anthony K.L. Leung 
Thesis Reader: 





 Great thanks are due to Dr. Anthony K.L. Leung, who has been a patient and 
optimistic mentor. He has instilled in me an appreciation for rigorous scientific 
examination both in and out of the lab. Leung lab members Dr. Yoshinari Ando, Casey 
Daniels and Temitope Gafaar have been helpful, engaged and supportive of my project. 
 Dr. Jürgen Bosch, my thesis reader, gave me the experience I needed to join this 
degree program by allowing me to work in his lab for the two years prior. Without the 
knowledge of protein structural biology I learned in his lab, this project would not have 
been feasible. 
 Finally, I would like to thank my wife, Adelaide-Ulricke Paulina Hain, my 




Table of Contents 
Abstract ……………………………………………………………………………..…… ii 
Acknowledgements ………………………………………………………….………….. iv 
List of Tables …………………………………………………………………………… vi 
List of Figures ...........................................................................................................…... vii 
List of Abbreviations …………………………………………...…………..…………. viii 
Background & Introduction …………………………………………………………...… 1 
Materials & Methods ………………………………………………………...………… 12 
Results & Discussion ………………………………………………………...………… 26 
Future Directions …………………………………………………………………....…. 37 
Figures ………………………………………………………………………………..… 39 
References …………………………………………………………………………….... 47 




List of Tables 
Table 1. Overview of PARP family proteins ……………….………………………….... 5 




List of Figures 
Figure 1. Diagram of poly(ADP-ribose) synthesis and degradation ……………..…….... 9 
Figure 2. ARH3 purification ….……………………………………………...………… 39 
Figure 3. PARP-12cat purfication …………………......……………………...………… 40 
Figure 4. Purified ARH3 is an active glycohydrolase …..…………………………...… 41 
Figure 5. Purified PARP-12cat is an active mono(ADP-ribose) transferase .…...….…… 42 
Figure 6. Ago2 mono(ADP-ribosyl)ation by PARP-12cat ……….……………………... 43 
Figure 7A. Ago2 poly(ADP-ribosyl)ation by PARP-5a ...……………...……………… 44 
Figure 7B. Ago2 poly(ADP-ribosyl)ation by PARP-5a ……………………...…….….. 45 
Figure 8. Ago2-mediated RNA cleavage assay …………………………………...…… 46  
viii 
 
List of Abbreviations 
ARH3                                                                                     poly(ADP-ribose) hydrolase 3 
ARTD                   ADP-ribosyltranferase 
BME                                                                                                         β-mercaptoethanol   
DTT                                                                                                                   dithiothreitol 
FPLC                                                                              fast protein liquid chromatography 
GST                                                                                                glutathione S-transferase 
IPTG                                                                        isopropyl β-D-1-thiogalactopyranoside 
kDa                                                                                                                        kilodalton 
LB                                                                                                                        Luria broth 
MAR                                                                                                        mono(ADP-ribose) 
MART                                                                                   mono(ADP-ribose) transferase 
NAD+                      nicotinamide adenine dinucleotide 
PAR                                                                                                           poly(ADP-ribose) 
PARG                                                                               poly(ADP-ribose) glycohydrolase 
PARP                                                                                     poly(ADP-ribose) polymerase 
RISC                                                                                  RNA-induced silencing complex 
SDS-PAGE                              sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
TRF1                                                                                 telomeric repeat binding factor-1 









Background & Introduction 
 
1.1 MicroRNA and Argonaute 
MicroRNAs are short, non-coding RNAs involved in post-transcriptional gene 
regulation. After processing, a mature microRNA (miRNA) is 18-25 nucleotides long and 
single-stranded. It joins a complement of proteins, the RNA-induced silencing complex 
(RISC). In humans, the RISC-mediated miRNA pairs imperfectly to the 3' UTR of 
transcribed mRNA, inhibiting translation or initiating cleavage. Because the pairing is 
imperfect, each miRNA can bind multiple mRNA targets, allowing it to regulate multiple 
genes. Over 1500 miRNAs have been identified in humans (miRBase) (Griffiths-Jones et 
al, 2006), each one with the potential to regulate multiple genes, and is involved in 
regulating nearly all cellular activities (Liu et al, 2004; Meister et al, 2004). 
 MiRNAs may be transcribed from unique genes or from introns of protein coding 
genes by RNA polymerase II. These transcripts form a double-stranded hairpin known as 
a primary miRNA (pri-miRNA), stabilized by a double-stranded RNA binding protein. 
Still in the nucleus, the enzyme Drosha processes the pri-miRNA into a relatively shorter 
double-stranded hairpin structure of about 70 nucleotides, termed pre-miRNA. The pre-
miRNA may also be more directly formed as a spliced-out intron of a protein-coding 
mRNA. This pre-miRNA from either source is then exported from the nucleus. In the 
cytosol, the pre-miRNA joins one of four Argonaute proteins, forming the basis of the 
RISC. Its hairpin structure is cleaved by the RNase Dicer yielding a miRNA/miRNA* 
duplex. The complementary miRNA* strand is left behind and either degraded or can 
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become its own miRNA. The main "guide strand" remains with Argonaute. Now 
approximately 20bp and single-stranded, the guide strand is free to base-pair with 
mRNA, bringing Argonaute and various other RISC proteins along (Krol et al, 2010). 
Although the first few miRNAs discovered reduced protein expression by inhibiting 
mRNA translation, it now appears that at least 84% of the time, miRNA targets are 
directed for degradation (Guo et al, 2010). 
 Of the four Argonautes, only Argonaute2 (Ago2) has the ability to cleave target 
mRNA directly. Ago2 has endonuclease activity conferred by its PIWI domain toward 
the target’s phosphodiester bonds (Rivas et al, 2005). PIWI is found in a wide variety of 
RNA-interacting proteins. It contains a positively charged channel for RNA sugar-
phosphate binding and an RNase H-like fold for target cleavage (Parker et al, 2004). 
Ago2 and the other members of the Argonaute family mediate RNAi using both small 
interfering RNA (siRNA) and miRNA. Upon binding, Ago2 bends a miRNA, creating 
several functional domains within the miRNA. The seed sequence, nucleotides 2-8, is 
most important for mRNA target recognition. The 3’ complementary region adds further 
recognition (Wee et al, 2012). 
 
1.2 Poly(ADP-ribosyl)ation and PARP-5a 
ADP-ribosylation is a post-translational protein modification in which one or 
more ADP-ribose groups are covalently attached to an amino acid substrate (Fig. 1). 
Enzymes that catalyze this modification are termed poly(ADP-ribose) polymerases 
(PARPs), mono(ADP-ribose) tranferases (MARTs) or, more generally, ADP-
ribosyltranferases (ARTD) (reviewed in Vyas et al, 2013). PARPs hydrolyze NAD+ into 
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an ADP-ribose which is attached to the substrate with the nicotinamide left over. The 
ADP-ribose monomer may then be polymerized into linear or branching chains from 2-
200 subunits long (Bürkle, 2005). This modification is reversible by several 
glycohydrolases, described later. 
The founding member of the PARP family is PARP-1, well-characterized for its 
role in DNA damage recognition. In humans, seventeen PARPs have been identified 
based on homology to the PARP-1 catalytic domain. They have been divided into four 
subcategories based on domain structure: DNA-dependent, tankyrases, CCCH RNA 
binding and macroPARPs. Among these, PARPs 1-5a&b have been identified as able to 
build poly(ADP-ribose) chains. The remaining PARPs have identified or predicted 
mono(ADP-ribose) activity, and two are catalytically inactive (Gibson & Kraus, 2012). 
PARP-5a, also called Tankyrase1, was first identified as a telomere-associated 
protein with the ability to poly(ADP-ribosyl)ate (PARylate) telomeric repeat binding 
factor-1 (TRF1) (Smith et al, 1998). In addition to its characteristic C-terminal PARP 
domain, it contains 24 ankyrin repeats, a motif which mediates protein-protein 
interactions. PARP-5a has since been shown to localize to mitotic spindle poles, 
endocytic vesicles (Hsiao & Smith, 2008) and more recently to stress granules (Leung et 
al, 2011). PARP-5a interacts with substrate partners through its ankyrin repeats, which 
recognize an eight amino acid motif, RSPPDGQS (Guettler et al, 2011). This sequence, 
with some variability, has been identified in many potential substrates and validated in 
such proteins as TRF1, tumor suppressor AXIN1/2,  mitotic spindle regulator NUMA1, 
apoptosis regulator MCL1 (Guettler et al, 2011). The catalytic PARP domain of PARP-5a 
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is similar to other PARPs and centers around a catalytic triad of histidine, tyrosine and 













PARP-1 1  DNA-dependent PAR Nuclear 
PARP-2 2  DNA-dependent PAR Nuclear 
PARP-3 3  DNA-dependent PAR (pred) Nuclear 
PARP-4 4 vPARP unclassified PAR Nuclear 
PARP-5a 5 Tankyrase
1 




Tankyrase PAR Nuclear & 
cytosolic 
PARP-6 17  unclassified MAR (pred)  
PARP-7 14 tiPARP CCCH RNA-binding MAR (pred)  
PARP-8 16  unclassified MAR (pred)  
PARP-9 9 BAL1 macroPARP inactive  
PARP-10 10  unclassified MAR Nuclear & 
cytosolic 
PARP-11 11  unclassified MAR (pred)  
PARP-12 12  CCCH RNA-binding MAR Cytosolic, 
stress granule 
PARP-13 13 ZAP CCCH RNA-binding inactive Cytosolic, 
stress granule 
PARP-14 8 BAL2 macroPARP MAR Cytosolic, 
stress granule 
PARP-15 7 BAL3 macroPARP MAR (pred) Cytosolic, 
stress granule 
PARP-16 15  unclassified MAR (pred)  
(Gibson & Kraus, 2012; Kleine et al, 2008; Vyas et al, 2013) 
Table 1: Overview of PARP family proteins  
PARPs were identified based on their homology to the catalytic domain of PARP-1 and 
subdivided based on other structural features. If a member’s activity has not been shown, 
it is designated as predicted (pred).    
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1.3 Mono(ADP-ribosyl)ation, PARP-12 and PARP-13 
 Less is known about PARPs 6-16, which make up the CCCH and macroPARP 
subgroups, all of which are predicted to have mono(ADP-ribosyl)ating activity, though 
PARP-9 and PARP-13 are catalytically inactive (Kleine et al, 2008). Unlike PARPs, 
which use a glutamate in their catalytic triad, MARTs lack this glutamate and it is 
proposed that they make use of a glutamate on the substrate to complete the attachment 
(Kleine et al, 2008). Therefore, once the site is modified, the catalytic glutamate is no 
longer available to assist transfer of any further ADP-ribose groups to lengthen the chain. 
 In humans, MAR is involved in transcription regulation through modification of 
histones and histone deacetylases (Feijs et al, 2013). Among the PARPs which localize to 
stress granules are PARPs 12 and 13. Overexpression of PARP-12 or PARP-13 results in 
a decrease of miRNA-mediated translation repression activity (Leung et al, 2011). Both 
also have demonstrated anti-viral activity, although the mechanism by which they do so 
is unknown. PARP-12 is expressed in two isoforms, one with and one without its PARP 
domain, but only the full-length product is able to inhibit viral replication(Atasheva et al, 
2012). PARP-13 also exists in two isoforms and requires its PARP domain to inhibit 
alphavirus replication by inducing innate immune responses (Kerns et al, 2008). It may 
also have an antiviral role without its PARP domain, as it has been shown to be 
selectively induced by 5’-triphosphate modified RNA (Hayakawa et al, 2010). 
Furthermore, the catalytic domain of PARP-13 may not have any ADP-ribose transferase 
activity at all (Leung et al, 2011). Unlike other recombinantly expressed catalytic 




1.4 PARPs and Ago2 colocalize at stress granules 
Argonaute proteins are modified by PAR under normal conditions. Upon stress, 
PARylation of Ago2 increases, leading to a decrease in its miRNA-mediated repression. 
This modification only occurs when the mRNA-binding PIWI domain is present, 
suggesting that the modification happens on this domain or that mRNA binding is 
necessary for PAR modification. During stress, Ago2 localizes to stress granules in the 
cytoplasm along with two isoforms of poly(ADP-ribose) glycohydrolase, PARG99, 
PARG102 and five PARPs: 5a, 12, 13, 14 and 15.  Overexpression of PARP-12, 13.1 and 
13.2 led to a decrease in miRNA activity. The mechanism for PARP-13-mediated 
miRNA repression is unclear because PARP-13.1 has not been shown to have an active 
PARP domain and PARP-13.2 lacks this domain altogether. These PARPs themselves are 
ADP-ribosylated, creating a complex network of cross-regulation (Leung et al, 2011). 
Ago2 IP extract, mixed with cell extracts overexpressing PARP combinations indicate 
that 5a/12, 5a/13.2 and 12/13.2 resulted PARylation greater than that of PARP-5a alone 
(unpublished). 
 
1.5 Reversal of PARylation 
 PARylation is reversed by several identified glycohydrolases, poly(ADP-ribose) 
glycohydrolase (PARG) and poly(ADP-ribose) hydrolase 3 (ARH3). The competition 
between PARPs to build PAR chains and the hydrolases to degrade them provides a 
mechanism for fine tuning of PAR regulation.  
PARG cleaves ribose-ribose bonds between PAR subunits (Lin et al, 1997), 
shown in Figure 1, but cannot cleave the terminal monomer from its protein substrate 
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(Slade et al, 2011). PARG mRNA is alternatively spliced to produce at up to four 
isoforms, all of which share the catalytic domain. The full length product, hPARG111 
(named for its molecular weight) localizes to the nucleus, while hPARG102 and 
hPARG97 are cytoplasmic (Meyer-Ficca et al, 2004). A fourth isoform, hPARG60 was 
reported to be found at the mitochondria (Meyer et al, 2007). The mRNA for hPARG60, 
was found to be spliced into an even shorter version, hPARG55, which is present at the 
mitochondria but not active there (Niere et al, 2012). 
ARH3 is a distinct glycohydrolase, sharing 19% sequence identity to PARG in its 
catalytic domain. Its crystal structure (Mueller-Dieckmann et al, 2006) reveals that its 
catalytic fold is unique from that of PARG (Kim et al, 2012). It is specific for PAR but 
not MAR, but with only approximately 10% of the efficiency of PARG in vitro (Oka et 
al, 2005). ARH3 is present in the cytosol, nucleus and mitochondria. Its N-terminus 
carries a mitochondrial localization signal, and it is active in the mitochondrial matrix 




Adapted from (Luo & Kraus, 2012) 
 
Figure 1: Diagram of poly(ADP-ribose) synthesis and degradation 
Members of the PARP family cleave the nicotinamide moiety from substrate NAD+ (A), 
resulting in ADP-ribose (B). A MART or PARP can attach it to an amino acid substrate, 
but only PARPs can elongate the chain (C). PAR chains can be linear or branched, 
depending on catalytic ability of the PARP. The PAR 2-mer shown above is a linear 
chain, but a branching chain could be built from the site indicated. PAR is degraded by 
glycohydrolases PARG and ARH3 between ribose groups.  
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1.6 Reversal of MARylation 
 Although it was long known that mono(ADP-ribosyl)ation (MARylation) could 
be reversed, it was only recently that several proteins with the ability to remove MAR 
modifications were discovered (hydrolysis site shown in Fig. 1). The first, C6orf130, was 
discovered in the context of neurodegeneration. When its gene is mutated with a 
premature stop codon, a truncated protein product results in a phenotype characterized by 
seizures and severe neurodegeneration. This defect is linked with a loss of the ability to 
cleave MAR (Sharifi et al, 2013). Two other proteins, MacroD1 and MacroD2, were 
subsequently identified. All three proteins carry a macrodomain, a domain known to bind 
MAR and PAR. Each is able to hydrolyze MAR from auto-modified PARP-10, a 
mono(ADP-ribose) transferase (Rosenthal et al, 2013). C6orf130 has limited ability to 
hydrolyze PAR chains (Sharifi et al, 2013), whereas MacroD1 and MacroD2 cannot 
(Rosenthal et al, 2013). MacroD2 was further characterized as having the ability to 
remove the terminal monomer from PARP-1 after the longer PAR chain was treated with 
PARG (Rosenthal et al, 2013). The presence of MacroD2 can inhibit the ability of PARP-
1 to form PAR chains (Jankevicius et al, 2013), adding another layer of regulation to the 
ADP-ribose modification system. Although all three proteins have similar activity in 
vitro, MacroD1 localizes to the mitochondria, and the neurological role of C6orf130 
suggests their environments and substrates may differ (Feijs et al, 2013). 
 
1.7 Conclusion 
 Previous work strongly suggests a model in which, under stress conditions, Ago2 
is sequestered to stress granules where it is PARylated. While PARylated, Ago2 would 
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be unable to mediate miRNA induced silencing, allowing potential mRNA targets to be 
translated in response to the stress situation. There are several levels of fine-tuning within 
this model. Ago2 could be MARylated or PARylated, perhaps resulting in different levels 
of modification, or MARylation could promote faster PARylation by getting the chain 
started. This would depend on the presence of MARTs like PARP-12 or PARPs like 
PARP-5a. PARP-5a itself may need a boost from PARP-12 or PARP-13.2 to PARylate 
Ago2, discussed in section 3.5. Furthermore, all of these PARPs can be MARylated and 
PARylated by themselves or other PARPs, likely affecting in some way their ability to 
modify Ago2. Finally, the presence or absence of PARG in its various isoforms or ARH3 
gives yet another mechanism for regulation. The potential network of cross-modification 
and reversal is complex. The aim of this project is to isolate components in an in vitro 
setting to verify the hypotheses generated by previous work. Then, step by step, the 
network can be rebuilt, examining the effect of each component and its effect on the 
overall system. Here, the purification and activity of PARP-12 and ARH3 are described. 
This thesis will outline the progress toward MARylating and PARylating Ago2. Finally, a 
miRNA-guided Ago2 cleavage assay is reconstituted. This work builds the necessary 
components for an in vitro reconstruction of events occurring at stress granules and more 






Materials & Methods 
 
2.1 Protein Expression and Purification 
2.1.1 ARH3 Expression and Purification 
 Expression and purification of human protein ADP-ribosylhydrolase (ARH3) in 
E. coli followed published methods (Kernstock et al, 2006). The expression plasmid was 
obtained from Joel Moss (Oka et al, 2005). The vector, pGEX-2T contains a glutathione 
S-transferase (GST) tag and a thrombin cleavage site, followed by the coding sequence of 
ARH3 and an Ampicillin resistance gene for selection. ARH3 is 39kDa (Oka et al, 2005) 
and GST is 26kDa, resulting in a fusion product of 65kDa. Approximately 100ng plasmid 
was transformed into 50μL chemical-competent Rosetta 2(DE3) E. coli. Rosetta 2 cells 
have chloramphenicol resistance on a plasmid optimizing for expression of eukaryotic 
codons. After transformation, the cells were used to inoculate 5mL LB containing 
50μg/mL ampicillin and 35μg/mL chloramphenicol. This starter culture was grown 
overnight at 37ºC, shaking at 200rpm. E. coli was pelleted by centrifugation and 
resuspended in 50mL LB with the same concentrations of antibiotics. Growth continued 
at 37ºC with shaking. When the culture was visibly turbid, the cells were again pelleted 
by centrifugation and resuspended in 1L LB with antibiotics and 50μL antifoam. As the 
culture grew, the optical density at a wavelength of 600nm was periodically measured by 
spectrophotometer. When OD600 reached 0.7, protein expression was induced with 
0.5mM IPTG. The temperature was lowered to 20ºC and expression continued overnight. 
13 
 
All following purification steps were carried out at 4ºC or on ice unless specified. 
Cells were harvested by centrifugation at 4500rpm for 20 minutes and resuspended in 
35mL lysis buffer containing 50mM Tris-HCl (pH 8.0), 150mM NaCl, 10mM MgCl2, 
0.1%v/v Triton X-100, 3mM BME, EDTA-free protease inhibitor cocktail (Roche) and 
200 units DNase I (Roche). Cells were lysed by mechanical homogenization (Avestin 
EmulsiFlex-C5) and clarified by centrifugation at 18000rpm for 40 minutes. The 
supernatant was collected and incubated while rocking with 1mL glutathione agarose 
beads (Sigma) for 30 minutes. The supernatant/bead slurry was applied to an open gravity 
flow column. The flow-through was collected for later analysis. Beads in the column 
were washed with 10 column volumes of lysis buffer followed by 10 column volumes of 
the same buffer without Triton X-100. ARH3 was cleaved from GST on-column by 
addition of 10 units of thrombin (GE Healthcare) in 1mL wash buffer. The cleavage 
reaction was incubated at room temperature for 4 hours with occasional swirling. The 
buffer was collected, followed by 4x1mL washes to clear additional cleaved protein. 
Remaining protein was eluted with 20mM reduced glutathione, 50mM Tris-HCl (pH 8.0), 
75mM NaCl, 10mM MgCl2 and 3mM BME. Whole cells, insoluble fraction, column 
flow-through, wash, each of the five cleaved elutions and the uncleaved elution were 
analyzed on a 12% SDS-PAGE minigel with a size marker (PageRuler broad range 
prestained protein ladder). The gel was rinsed in water, stained with coomassie 
(SimplyBlue SafeStain), destained in water and scanned on the Odyssey (Fig. 2). The five 
1mL cleaved fractions were pooled and concentrated to 500μL in a 10kDa-cutoff 
concentration tube. The concentrated sample was centrifuged at top speed in a tabletop 
centrifuge for 10 minutes to pellet any precipitated protein. Supernatant was loaded onto 
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a Superdex 200 size exclusion column (GE Healthcare) using the Äkta FPLC system. 
Protein was eluted by flowing buffer containing 50mM Tris-HCl (pH 8.0), 150mM NaCl, 
10mM MgCl2 and 3mM BME. Eluate was collected in 500μL fractions. Fractions 
corresponding to peaks measured at an absorbance of 280nm were analyzed by SDS-
PAGE as described above (Fig. 2). A peak which eluted at an approximately expected 
size from the S200 column corresponded with the 39kDa band on SDS-PAGE. Fractions 
corresponding to this peak were pooled and concentrated in a 10kDa-cutoff filter. Size 
exclusion buffer with 10% glycerol was used to adjust the concentration to 5mg/mL as 
measured by NanoDrop. The sample was aliquoted, snap-frozen in liquid nitrogen and 
stored at -80ºC. 
 
2.1.2 PARP-12cat Expression and Purification 
 Expression and purification of the catalytic domain of human PARP-12 in E. coli 
roughly followed methods available online 
(http://www.thesgc.org/structures/details?pdbid=2PQF/). The plasmid construct was 
obtained from Torun Ekblad. The pNIC-bsa4 vector contains a 6xHistidine tag and 
Tobacco Etch Virus (TEV) cleavage site followed by the open reading frame, where 
PARP-12cat is inserted. This encodes for a 219 amino acid, 25kDa protein. The construct 
was transformed into Rosetta 2 E. coli and a glycerol stock was made. The glycerol stock 
was poked to inoculate a starter 5mL overnight culture in LB with 50μg/mL kanamycin 
and 35μg/mL chloramphenicol. It was grown at 37ºC with shaking as described above. 
This culture was increased to 50mL LB with antibiotics until it was visibly turbid. It was 
then increased to 1L and later to 2L. When OD600 reached 0.7, the temperature was 
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lowered to 18ºC and allowed to equilibrate for 30 minutes before inducing with 0.5mM 
IPTG. Expression continued overnight. 
 Cells were harvested by centrifugation and resuspended in 40mL lysis buffer 
containing 50mM HEPES-NaOH (pH 8.0), 500mM NaCl, 10mM imidazole and 10% 
glycerol. The mixture was snap-frozen in liquid nitrogen and stored at -80ºC. To purify, 
the cells were thawed at room temperature then transferred to ice, after which all steps 
were carried out at 4ºC or on ice. DNase I and protease inhibitor cocktail was added 
before lysing by homogenization. Lysate was clarified by centrifugation and the 
supernatant was collected. The supernatant was loaded into a syringe and manually 
pumped over a 5mL nickel-charged HisTrap Crude FastFlow immobilized-metal affinity 
column (GE Healthcare). The column with bound protein was washed with 6 column 
volumes lysis buffer, followed by 2x5mL elutions with lysis buffer containing 300mM 
imidazole. Whole cells, insoluble and soluble fractions, nickel flow-through, wash and 
the elutions were run on 12% SDS-PAGE (Fig. 3A). The two elutions were combined 
and dialyzed overnight with 500mL dialysis buffer containing 30mM HEPES-NaOH (pH 
7.5), 300mM NaCl and 10% glycerol. The elutions were extremely impure, so they were 
reloaded onto the nickel column, washed with 20 column volumes lysis buffer and eluted 
in 5mL steps of increasing imidazole concentration: 20mM, 50mM, 100mM, 150mM, 
200mM, 250mM and 300mM. SDS-PAGE revealed PARP-12cat to be primarily in the 
100mM and 150mM steps, along with proteins of various other sizes (Fig. 3B). These 
fractions were combined and dialyzed overnight in dialysis buffer. The sample was 
further purified by ammonium sulfate precipitation. Solid ammonium sulfate was added 
while stirring on ice to 10% then spun at 10,000xg. The supernatant was collected and the 
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pellet was resuspended in 5mL lysis buffer. This was repeated with the supernatant to 
steps of 20%, 30%, 40% and 50%. All protein, including PARP-12cat and impurities, 
precipitated at 40% and 50% ammonium sulfate (these two steps had similar coomassie 
gel profiles, seen in Fig. 3C). They were combined and dialyzed overnight into 500mL 
buffer A, containing 20mM HEPES-NaOH (pH 7.5), 10% glycerol and 2mM BME. After 
dialysis, the sample appeared cloudy, so it was spun at 500xg to pellet precipitated 
protein. The supernatant was collected and the pellet was saved for analysis. Clarified 
supernatant was hand-loaded by syringe on to a 5mL HiTrap Q FastFlow anion exchange 
column pre-equilibrated with buffer A. The column was washed with 2 volumes buffer 
A, then attached to the Äkta FPLC. Protein was eluted using a linear gradient of 0-1M 
NaCl over 10 column volumes and collected in 1mL fractions. The dialysis pellet, 
supernatant (HiTrap Q input), Q column flow-through and fractions corresponding to 
measured peaks were analyzed by SDS-PAGE (Fig. 3D). PARP-12cat was observed in the 
Q wash and an early elution peak. These two fractions were kept separate. The wash was 
concentrated in a 10kDa-cutoff tube to 1.3mg/mL and the elution was concentrated to 
0.7mg/mL. Each sample was aliquoted in separately labeled tubes, snap frozen in liquid 
nitrogen and stored at -80ºC. 
 
2.1.3 PARP-5a Expression 
 Expression and purification of human PARP-5a (TNKS1) in insect cells was 
based on protocols provided by Susan Smith (Smith et al, 1998). Reagents, insect cells, 
equipment and instruction was provided by Yana Li in the Eukaryotic Cell Expression 
Facility at the Johns Hopkins School of Medicine. Baculovirus expanded once (P2) was 
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obtained from the Smith lab. This baculovirus plasmid (bacmid), contains the coding 
sequence for PARP-5a under a polyhedron promotor. A viral titer number was not 
available. 175µl of this stock was used to infect 500mL of Spodoptera frugiperda Sf9 
cells at a density 2x106/mL. The cells were incubated at 27°C, in a spinner flask to 
maintain the cells in suspension, for approximately 72 hours. At this point, roughly half 
the cells had died from viral infection, indicating successful viral propagation. The cells 
were spun down; the supernatant (media with virus) was collected and separated into 
50mL aliquots. 25mL of this third passage (P3) was used to infect 200mL Sf9, this time 
optimizing for protein expression as opposed to virus propagation. Half of the culture was 
removed at 42 hours (at a density of 1.7x106/mL) while the remainder was allowed to 
incubate until 70 hours (2x106/mL). Both were spun down immediately after harvesting. 
The supernatants were discarded; the pellets were flash-frozen in liquid nitrogen and 
stored at -80ºC. The samples were handled in parallel but kept separate during 
purification. 
 The pellets were thawed in cold lysis buffer containing 20mM Tris-HCl (pH 8.0), 
500mM NaCl, and 5mM imidazole. Cells were lysed by sonication with three cycles of 
30 seconds on, 30 seconds off. Lysate was clarified by centrifugation. The supernatant 
was syringe-pumped over a 5mL nickel-charged HisTrap FastFlow Crude column (GE). 
The column was washed with 10 volumes lysis buffer, then eluted with 2x5mL lysis 
buffer containing 300mM imidazole. Fractions were analyzed by SDS-PAGE, but no 
enrichment was observed at the expected size. A western blot was then performed with 
the same fractions, revealing an enriched band at the expected size, but also many other 
bands of various sizes. 
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 Optimization of expression conditions was undertaken to produce more favorable 
results. 1L of Sf9 cells was split into four smaller spinner flasks. The four smaller 
cultures were infected with varying amounts of P3 virus: 2.5mL, 5mL, 10mL and 25mL. 
Half of each culture was harvested at 72 hours while the remainder was allowed to 
incubate until 96 hours, with the exception of the culture infected with 2.5mL P3, in 
which most cells were dead after 72 hours and were therefore harvested entirely at that 
time. This yielded 7 conditions, which were resuspended in lysis buffer before snap-
freezing and stored at -80ºC until ready for purification. While thawing, protease 
inhibitors and DNase were added. Whole cells were analyzed by SDS-PAGE and western 
blot. No enrichment was visible in coomassie staining. The western blot, with PARP-5a-
expressing HeLa cells and uninfected Sf9 cells used as controls, confirmed expression of 
PARP-5a, but did not provide better expression conditions. Cells were pooled, lysed by 
sonication and clarified by centrifugation. Supernate was affinity-purified by HisTrap 
Crude Fast Flow and analyzed by SDS-PAGE. The HisTrap elution showed proteins of 
all sizes. The elution was concentrated to 500μL in a 30kDa-cutoff tube and loaded onto 
an S200 size exclusion column using the Äkta FPLC. Concentration and S200 elution 
was done in buffer containing 20mM HEPES-NaOH (pH 8.0), 100mM KCl, 3mM 
MgCl2 and 2mM BME. Fractions containing proteins roughly corresponding to the 
expected size of PARP-5a were collected, concentrated with 10% glycerol to 5mg/mL, 
flash-frozen in aliquots and stored at -80ºC, despite being highly impure. 
 In the third expression attempt, P4 virus supplied by Titia deLange was used to 
directly infect 100mL of Sf9 cells. After lysing, the pellet was resuspended in buffer 
containing 1% NP-40 to aid in solubility. 
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 The fourth expression used 10% fetal bovine serum during Sf9 growth which was 
washed away with media prior to lysis. Cobalt-charged TALON resin was substituted in 
the affinity capture step. Anion exchange chromatography using HiTrap Q FF was also 
tested. The insoluble fraction from this expression was resuspended in 8M urea to test the 
possibility of refolding insoluble PARP-5a. This was loaded on to nickel HisTrap 
FastFlow Crude, followed by washes of 7M, 6M, 5M, 4M and 1M urea in lysis buffer, 
then lysis buffer only. 
 Sf21 cells were tested in the fifth expression with de Lange lab P4 virus, but the 
yield was not improved. At this point, expression was put on hold until fresh bacmid 
could be produced. Numerous attempts to clone PARP-5a into a pre-bacmid pFastBac1 
vector were unsuccessful. 
 
2.2 Activity Assays 
2.2.1 ARH3 Activity Assay 
 The ability of ARH3 to cleave PAR chains was tested on automodified PARP-1. 
The conditions for PARP-1 automodification and subsequent digestion with commercial 
PARGcat (Trevigen) were developed by Casey Daniels. Purified 6xHis-PARP-1 was 
provided by Casey. Several rounds of optimization generated consistency between 
replicates. First, 500ng (per reaction) PARP-1 was attached to 0.5μg MagneHis magnetic 
nickel beads (Promega) for 2 hours, rotating at 4ºC in attachment buffer containing 
50mM Tris-HCl (pH 7.4), 1mM ADP-HPD (a PARG inhibitor), 1% Tween-20, 0.2mM 
DTT, 10% glycerol, 10mM MgCl2 and protease inhibitors. With the protein attached, the 
beads were isolated against a magnet while the buffer was changed to automodification 
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buffer containing 20mM Tris-HCl (pH 7.5), 50mM NaCl, 50μM TCEP and 5mM MgCl2. 
A mixture of 32P-labeled and unlabeled NAD+ was added to each condition, to be cleaved 
by PARP-1 and build into PAR chains for subsequent detection. The final NAD+ 
concentration was 19μM, 1% of which was radioactive. To catalyze PARP-1 activity, 
blunt-end annealed DNA oligonucleotides were added to a working concentration of 
1μM. The PARylation reaction proceeded for 30 minutes at 25ºC. An excess of unlabeled 
NAD+ was added to promote the formation of the longest PAR chains possible, bringing 
the total concentration of NAD+ above 2.5mM. After an additional hour at 25ºC, the 
beads/proteins were isolated by magnet, the buffer was removed and the beads were 
washed twice in 50μL wash buffer containing 50mM sodium phosphate (pH 7.4), 
200mM NaCl, 5mM imidazole and 1% Tween-20. After washing, the buffer was 
replaced with digestion buffer containing 50mM potassium phosphate (pH 7.5), 50mM 
NaCl, 10mM MgCl2, 1mM BME, 10% glycerol, 0.1% Triton X-100 and 1mM 3-AB (a 
PARP inhibitor). ARH3 at varying concentrations or 5ng PARGcat was added. After 
incubating for 2 hours at 25ºC, the buffer was removed and the beads were washed twice. 
Protein was eluted from the beads by boiling in SDS for 5 minutes at 95ºC in loading dye 
and analyzed by SDS-PAGE, followed by overnight autoradiography. This experiment 
was performed in duplicate. Controls included 500ng PARP-1 unattached input, attached 
unmodified PARP-1 carried through all washes and incubations, modified PARP-1 eluted 
immediately after modification, modified undigested PARP-1 carried through all steps 
and PARG digested (for comparison with ARH3). 
  
2.2.2 PARP-12cat Activity Assay 
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 The ability for PARP-12cat to auto-mono(ADP-ribosyl)ate was tested using a 
protocol adapted from PARP-1 automodification. One microgram per reaction 6xHis-
tagged PARP-12cat was attached to MagneHis magnetic nickel beads by incubating with 
rotation at 4ºC for 2 hours. The binding buffer was changed to automodification buffer 
and a mixture of labeled and unlabeled NAD+ was added. After 30 minutes of incubation 
at 25ºC, the beads were washed twice and eluted by boiling in SDS loading dye. Samples 
were analyzed by 12% SDS-PAGE and autoradiograph. PARP-1 was included as a 
positive control for ADP-ribosylation and to compare its PAR activity with PARP-12’s 
predicted mono(ADP-ribosyl)ation activity. Input and bead attachment controls were also 
included. PARP-12cat species from both the anion exchange flow-through and elution, 
described in section 2.2.1, were tested for activity. The elution, which showed activity, 
was tested again in a 6μg batch, with 1μg removed, washed and heated with SDS loading 
dye every 5 minutes for 30 minutes. 
 PARP-12cat was tested for the ability to mono(ADP-ribosyl)ate Ago2. Ago2, 
carrying endogenous insect cell RNA, was batch-bound to MagStrep beads overnight in 
binding buffer (buffers described in 2.2.1). The Ago2 was then split into six experimental 
conditions and mixed with PARP-12cat in various amounts. In three conditions, Ago2 was 
constant at 1μg, with 62.5ng, 250ng or 1μg PARP-12cat, resulting in molar ratios of 4:1, 
1:1 and 1:4. In the next three conditions, PARP-12cat was constant at 1μg with 250ng, 
1μg or 2μg Ago2, resulting in molar ratios 8:1, 4:1 and 2:1. The buffer was changed to 
automodification buffer and NAD+ was added to a concentration of 17.5μM, 1% 32P-
labeled. NAD+ was added to all conditions except Ago2 and PARP-12cat input lanes. This 
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was incubated for 30 minutes at 25ºC, washed twice, eluted in 15μL loading dye, boiled 
and analyzed by 12% SDS-PAGE. 
 
2.2.3 PARP-5a Activity Assay 
 PARP-5a (Tankyrase1) with a 6xHistidine tag was purchased from Trevigen. It 
was tested for the ability to auto-PARylate and to modify substrates TRF1 and 
Argonaute2 (Ago2). Automodification was tested using the PARP-1 automodification 
protocol, minus the DNA. Using 100ng per condition, PARP-5a was tested for the ability 
to PARylate 500ng of known substrate TRF1 (Smith et al, 1998), 1µg Ago2 or 1μg BSA. 
Magnetic nickel beads were used for buffer changes and wash steps with PARP-5a only, 
with TRF1 and with BSA. MagStrep beads were used with PARP-5a with Ago2, as the 
MagStrep beads were observed to bind all protein indiscriminately. The concentration of 
NAD+ was tested at 40μM (0.75% radioactive), 4μM (7.5% radioactive) and 0.3μM 
(100% radioactive). To further optimize modification of Ago2, several additions were 
tested: 536ng total RNA extracted from 293T cells provided by Yoshinari Ando or 
200μL lysate from 293F cells over-expressing GFP-PARP-13.2 or GFP only, provided by 
Temitope Gafaar. Samples were analyzed by 8% SDS-PAGE and autoradiograph. 
 
2.2.4 Argonaute2 cleavage assay 
 Two varieties of Argonaute2 (Ago2) were provided by the Leemor Joshua-Tor: 
with and without endogenous insect cell miRNA. Both were tested against two RNA 
targets: a perfect complement of bantam miRNA (5'-
guaucaaaaucagcuuucacaaugaucucaacguucaau-3') and an imperfect target meant to serve 
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as a negative control (5'-guaucaaaauagcuuucaccccugauacucaacguucaau-3'). First, Ago2 
with RNA was tested against these targets. Next, both species of Ago2 were incubated 
with bantam (5'-ccgguuuucgauuugguuugacu-3') (Thermo Scientific) before testing them 
against the targets. Targets were phosphorylated using T4 polynucleotide kinase (New 
England Biolabs) and 32P labeled ATP (Perking Elmer). Bantam was phosphorylated with 
non-radioactive ATP. 2pmol Ago2 (200ng) was incubated with 2pmol bantam and 
20units (1μL) SUPERase In RNase inhibitor (Ambion) and incubated at 26ºC for 90 
minutes. This and all subsequent steps took place in buffer containing 40mM potassium 
acetate pH 7.4, 2mM MgCl2 and 1mM DTT. Now loaded with bantam, 0.15pmol or 
1.5pmol Ago2 was mixed with 0.15pmol target and 20 units RNase inhibitor at 30ºC for 
one hour. RNA was isolated by diluting the 10μL reaction with 190μL water, then mixing 
with 200μL buffer-saturated phenol pH 7.5 (Life Technologies). This was vortexed for 
one minute, then spun down at top speed on a tabletop centrifuge for 2 minutes to 
separate the phases. The upper aqueous phase was pipetted off, placed in a clean tube and 
mixed with 200μL of phenol:chloroform:isoamyl alcohol (25:24:1) pH 7.9 (Sigma). This 
was vortexed and spun as before. The aqueous layer was pipetted to a clean tube. RNA 
was precipitated by adding 20μL 3M sodium acetate pH 5.5, 1μL linear acrylamide, 
600μL absolute ethanol and incubating at -80ºC for 15 minutes. This was spun at top 
speed at 4ºC for 30 minutes. The supernatant was discarded. The pellet was washed in 
cold 70% ethanol, spun for 10 more minutes at 4ºC and the supernatant was again 
discarded. The pellet was allowed to dry in a fume hood for several hours at room 
temperature. When dried, the pellet was resuspended in RNA loading buffer (Ambion), 
heated for 2 minutes at 95ºC and cooled on ice. Samples were loaded onto a denaturing 
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self-poured 12% ureagel (gel components from Sequagel) and electrophoresed for 
approximately 2.5 hours at a constant power of 35W. A 10 base-pair DNA ladder 
(Invitrogen) and a 22 nucleotide RNA (provided by Yoshinari Ando), both 
phosphorylated with 32P ATP as described above, were run on the gel for size 
comparison. The gel was then exposed to autoradiography overnight. The autoradiograph 
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Results & Discussion 
 
3.1 ARH3 glycohydrolase activity 
 Expression of active human ARH3 was achieved on the second attempt. 
Optimizing induction to 0.5mM IPTG reduced the amount of insoluble protein observed 
in a primary attempt. The second expression was also the first time thrombin was used to 
cleave off the GST tag. After on-column cleavage, size exclusion purification and 
concentration, the final yield was approximately 1μg. Uncleaved GST fusion ARH3 was 
tested along with cleaved ARH3 in the first assay. While uncleaved protein did not 
appear to have the same level of activity as cleaved protein, the controls were not 
consistent between the duplicates. In subsequent assays, controls were optimized, but 
uncleaved protein was not tested further because of the low yield and concentration. 
Figure 4 shows the results of varying amounts of ARH3 cleaving PAR chains on 
automodified PARP-1. In the coomassie stain, PARP-1 unmodified input and bead 
attachment control lanes show that in addition to full length protein, indicated at 113kDa, 
there are many fragments extending down to 50kDa. During automodification, PAR 
chains are built on these fragments, in addition to the full-length protein, enhancing the 
smearing effect visible in the autoradiograph (Fig. 4, right). In the coomassie stain, 
PARP-1 disappears because of the variable size PAR chains, but appears as a smear on 
the autoradiograph. After treatment with PARGcat, the chains are cleaved down to the 
terminal ADP-ribose moiety; distinct bands reappear and correspond with autoradiograph 
bands. When PARylated PARP-1 was mixed with 0.5μg ARH3, the smear decreases 
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somewhat. With 5μg ARH3, the autoradiograph smear is replaced by distinct bands, 
which also reappear on the coomassie stain, similar to the profile observed with PARGcat 
treatment. Unlike PARGcat, 5μg ARH3 leaves a band of high molecular weight. Finally, 
with 50μg ARH3, the radioactive signal is totally ablated. 
 
Discussion 
 Treatment of PARylated PARP-1 with increasing amounts of ARH3 demonstrates 
the ability of ARH3 to cleave PAR chains from PARP-1, though with significantly less 
efficiency than PARGcat. 5μg of ARH3 is necessary to mimic the results of cleavage with 
5ng PARGcat, a thousand-fold increase by weight (though they are similar in size, so their 
molarity is similar). This is far less activity than previously reported (Oka et al, 2005). 
Even at this level of ARH3, there is some residual smearing, along with a high molecular 
weight band in the autoradiograph. Another difference is the intensity of the bands 
between 5μg ARH3 and PARGcat. In the PARGcat condition, the bands are distinct and 
the signal is strong. The ARH3-generated bands not only show smearing in between, the 
bands themselves are weaker. Considering this, it seems possible that the activity of these 
two enzymes is not the same. Further, in the condition using 50μg ARH3, the absence of 
any signal could indicate that terminal ADP-ribose moieties have been removed, but this 
would need to be verified by further experiments, discussed below in section 4.1. This is 
an unexpected result, as it was previously reported that ARH3 is unable to reverse 
mono(ADP-ribosyl)ation (Oka et al, 2005).  
 
3.2 PARP-12cat mono(ADP-ribose) transferase activity 
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 Although the first purification yielded enough protein for activity assays, more 
was needed for subsequent tests. Several steps from the initial purification appeared 
appropriate for optimization. The ammonium sulfate precipitation, in which all 
previously soluble proteins precipitated together, was dropped. Because a smaller band 
below the main 25kDa PARP-12cat band appeared to enrich after anion exchange, further 
purifications included protease inhibitors not only during lysis and the affinity capture 
step, but also through to anion exchange, on the hypothesis that it may be a result of 
proteolytic cleavage. Because the theoretical isoelectric point (pI) of PARP-12cat, 
calculated by Expasy ProtParam, is 6.86, the anion exchange buffer was increased in pH 
from 7.5 to 8.0, further from the pI, to promote tighter binding to the resin. This resulted 
in an elution peak from the anion exchange column at a similar salt concentration, but 
with a lower molecular weight. The only protein eluting at the correct size from this 
anion exchange step eluted with an abundance of higher-weight contaminants, and 
appeared smeared, which PARP-12cat had not displayed before. The lower molecular 
weight protein was assayed for activity, but none was observed. Expression and 
purification was repeated, but the result was the same. The plasmid construct was then re-
transformed into Rosetta 2 E. coli and expressed directly without freezing, in case the 
glycerol stock had degraded in quality after long-term deep freeze, but the result did not 
improve. Anion exchange fractions from that (fourth) purification were analyzed by 
western blot with an anti-his tag primary antibody. Early fractions showed distinct bands 
at 25kDa on the blot, but did not show activity when tested. Finally, a nickel-charged 
5mL HiTrap Chelating HP column (GE) was substituted in the affinity capture step. This 
yielded the cleanest elution yet. This was further purified by anion exchange, with a pH 
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7.5 as in the original purification. As in the first purification, a protein of 25kDa eluted at 
low salt. This was concentrated to 1.5mg/ml, aliquoted, flash frozen and stored at -80ºC. 
Unfortunately, although this purification was the most promising yet since the first 
attempt, it showed no activity when tested. Additionally, although it measured at 
1.5mg/ml by NanoDrop spectrophotometry (adjusted for a predicted extinction 
coefficient of 1.8), when 1μg was loaded on SDS-PAGE alongside 1μg of the original 
purification, the new batch gave a much weaker band. 
 The first purification was tested for activity, using either 1μg of the anion 
exchange (Q) flow through or elution, and 500ng PARP-1 as a control. In Figure 5A, 
PARP-1 is observed to PARylate as in the ARH3 assay, with a disappearance on the 
coomassie stain and a smear on the autoradiograph. By contrast, when PARP-12cat anion 
elution was mixed with 32P NAD+, the coomassie band did not disappear and the 
autoradiograph showed a discrete band directly on top of the coomassie band. This is 
consistent with mono(ADP-ribosyl)ation, showed previously with PARP-10cat (Kleine et 
al, 2008). This activity was not observed with protein collected from the anion exchange 
flow through. The smaller band that purified along with the PARP-12cat elution also 
exhibited an autoradiograph signal. The flow though fraction was not tested further. 
When the assay was repeated with 5 minute time points (Fig. 5B), the radioactivity signal 
increased at each time point up to 25 minutes. The 30 minute reaction looked weaker than 






 The first purification attempt for PARP-12cat appeared easy to improve upon, but 
after several rounds of optimization which failed to produce active enzyme, the changes 
were reversed in the hope of re-creating the initial results. The final purification appeared 
to work until it was assayed for activity. The only step from the original purification 
which was not repeated was the ammonium sulfate precipitation. This step may have 
altered the protein in such a way as to activate it, perhaps by rearranging due to increased 
hydrophobic interactions. Another unusual result is the discrepancy between the first and 
final purifications in regards to their measured concentration. When 1μg of each was 
incubated with 32P NAD+, then analyzed by SDS-PAGE and autoradiography, the later 
purification appeared much weaker by coomassie staining. This might be accounted for 
by the ammonium sulfate precipitation, which would have removed free nucleotides from 
the first purification, making the OD280 measurement more accurate of protein content. 
Considering that the fourth and fifth (final) purifications were able to yield a protein of 
25kDa which appeared by western blot against the 6xHis tag (in the fourth attempt), the 
fact they showed no activity is unexpected. The final purification should be tested again 
with a larger amount of protein to verify that it is not active. Perhaps its concentration, 
measured by NanoDrop, was not accurate and therefor gave a signal too weak to observe 
by autoradiography. The inability to produce more active PARP-12cat hindered later 
attempts to test the ability of PARP-12cat to mono(ADP-ribosyl)ate Ago2. 
  
3.3 PARP-5a expression and activity 
 Numerous attempts to purify PARP-5a from insect cells resulted in miniscule 
amounts of protein overwhelmed by contaminants. The elution from nickel-affinity 
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chromatography did not enrich for a protein of the expected size, 142kDa. Upon western 
blotting with an anti-PARP-5a antibody, a signal was visible, indicating it was expressed. 
Anion exchange and size exclusion chromatography were unable to improve purity 
because of such poor results from the affinity capture. Several resins, an imidazole 
elution gradient and cobalt instead of nickel were tested with no improvement. After six 
attempts over several months, expression was abandoned to focus on re-creating a fresh 
bacmid, a step often suggested in troubleshooting guides. Unfortunately, ligating PARP-
5a into pFastBac1, a pre-bacmid transfer vector failed despite repeated attempts. 
 Despite the impurity of the nickel affinity elutions, they were tested for activity, 
as described above for PARP-1. No activity was observed (not shown). 
 
Discussion 
Several factors may have contributed to the failure to express and purify active 
PARP-5a. The low expression levels may have been due to the old age of the virus 
provided from collaborator labs. Several insect cell protocol manuals recommended 
working with bacmid no more than a few months old. The efforts to create a new bacmid 
would have addressed this and also given the opportunity to add a second affinity tag. On 
the purification side, the abundance of nonspecific binding to nickel and cobalt affinity 
resins blocked progress beyond that first step. The only available resin that was not tested 
was the HiTrap Chelating HP, which improved specificity in the PARP-12cat purification. 
 
3.4 Argonaute2 ADP-ribosylation 
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 PARP-12cat, when mixed with Ago2, favored automodification activity over 
modification of Ago2 (Fig. 6). The Ago2 attachment control condition included 
radiolabeled NAD+ to ensure that the autoradiograph signal corresponding to Ago2 in the 
experimental conditions could not be attributed to spontaneous chemical modification. 
Modification of Ago2 appeared in each experimental condition when mixed with PARP-
12cat except one, when the molar ratio of Ago2 to PARP-12cat was 4:1. This was the only 
condition in which the amount of Ago2 was greater than PARP-12cat. In all other 
conditions, a radioactivity signal corresponded with Ago2, with no apparent smearing, 
suggesting mono(ADP-ribosyl)ation. The signal is strongest when Ago2 was 
overwhelmed by PARP-12cat at ratios of 1:4 and 1:8. There is a discrepancy between the 
two 1:4 conditions which cannot be accounted for. No signal corresponding to Ago2 or 
PARP-12cat is visible in the only condition in which Ago2 overwhelms PARP-12cat, at a 
ratio of 4:1. This may be due to error, as no PARP-12cat automodification is visible, or 
because the amount of PARP-12cat is too low at 62.5ng.  
 PARP-5a (purchased from Trevigen) showed minimal PARylation activity toward 
Ago2 when mixed in vitro. In Figure 7A, as NAD+ concentration is decreased, the 
radioactivity signal corresponding to TRF1 increases. With Ago2, as NAD+ decreases, a 
band corresponding to Ago2 becomes faintly visible on the autoradiograph. In both 
conditions, the activity of PARP-5a is primarily automodification, giving a much stronger 
signal than that of either substrate. With 0.3μM NAD+, the TRF1 autoradiograph signal 
smears upward slightly, but this is not apparent with Ago2. When 293F cell lysate 
overexpressing GFP was added to the PARP-5a/Ago2 reaction, a substrate protein of 
approximately 120kDa appeared and the PARP-5a automodification signal decreased. 
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When 293F cell lysate overexpressing GFP-PARP13.2 was added, the 120kDa substrate 
appearance and automodification decrease were accompanied by a smear of radioactive 
signal both above and below 120kDa, including an enriched band corresponding to Ago2 
(Fig. 7B). Adding 293T cell total RNA did not significantly change the profile of PARP-
5a with Ago2, except to decrease smearing somewhat. A control with PARP-5a and BSA 




 PARP-12cat appears to be able to mono(ADP-ribosyl)ate Ago2 in vitro (Fig. 6). 
The reaction strongly favored automodification in this test. This may be due to the 
concentrations of each protein in this particular reaction and should be verified. There 
was only one condition in which the concentration of Ago2 was greater than PARP-12cat, 
but since this condition failed to give any radiography signal, it is impossible to draw any 
conclusions as to whether the molar ratios of each protein contributed to the results. Two 
conditions had the same protein ratio but showed noticeably different signals. The 
purpose of this experiment was not necessarily to determine the kinetics of this 
interaction, but to optimize a protocol for mono(ADP-ribosyl)ation of Ago2. To achieve 
this, more replicates are needed and should include more conditions in which the 
concentration of Ago2 is greater than PARP-12cat, to determine whether the reaction can 
be shifted away from automodification. Unfortunately, limited amounts of active PARP-
12cat hindered that goal. 
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 As with PARP-12cat, PARP-5a favors automodification in the assay shown in 
Figure 7A. Its PARylation activity toward substrate TRF1 is more robust than toward 
Ago2 when they are mixed in the absence of other proteins in vitro. Although the 
autoradiography signal corresponding to TRF1 increases as overall NAD+ concentration 
decreases, the concentration of radiolabeled NAD+ remains the same. There are two 
possible explanations for this. The lower concentration of NAD+ could be pushing 
PARP-5a to favor modification of TRF1 over automodification. More likely, when the 
available NAD+ is entirely radioactive, as in the lowest concentration, PAR chains 
attached to TRF1 are more visible by autoradiography. An autoradiography signal 
corresponding to Ago2 is visible at all concentrations of NAD+ which is not present with 
PARP-5a alone, though this band is faint. The results seen in Figure 7B suggest that 
PARP-5a automodification is enhanced by the addition of other protein. PARP-5a is not 
visible in the coomassie stain, but can be seen at its expected size of 142kDa in the 
autoradiograph. The signal is faint when PARP-5a is alone, but is stronger when Ago2, 
293F cell lysate or BSA is present. 293F cell lysate appears to push PARP-5a toward 
favoring an unknown substrate of approximately 120kDa. The appearance of additional 
signal above and below this size when PARP-13.2 is overexpressed suggests it is 
enhancing PARP-5a activity, perhaps toward all available substrates in a broad fashion. 
This could be the case in stress granules, where PARP-13.2, PARP-5a and Ago2 
colocalize. Because PARP-5a has an RNA-binding domain, 293T cell total RNA was 
added to test whether it would increase PARP-5a activity toward Ago2, but that 
hypothesis was not supported here. 
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3.5 Argonaute2 cleavage activity 
 When incubated with its target, Ago2 loaded with endogenous insect cell RNA 
did not show visible cleavage activity by autoradiograph (not shown). Ago2 free of 
endogenous insect cell miRNA showed activity against its target when it was loaded with 
bantam miRNA, but not against a mutated target RNA. In the assay shown in Figure 8, 
the cleavage product of the bantam target is visible in lane number 4, where the target of 
bantam, labeled wild-type, is mixed with Ago2/bantam in a 1:5 molar ratio. While the 
full-length bantam target, at 40 nucleotides, makes up the majority of radiolabeled RNA 
visible in this condition, the cleavage product, predicted to be approximately 20 
nucleotides long, is enriched compared to the control lacking Ago2. In the control, 
several bands appear below the full length oligonucleotide, including one at the same 
height as the 20bp signal from the ladder. The experimental condition has this band as 
well, but is enriched for an oligonucleotide just above it such that the bands overlap 
somewhat. Unexpectedly, the condition in which the target was mixed with Ago2/bantam 
in a 1:1 molar ratio gave no radioactive signal at all, likely due to error. The last three 
lanes, with mutant bantam target, target with Ago2/bantam in a 1:1 ratio and a 1:5 ratio, 
respectively, are free cleavage of products, as expected. 
 
Discussion 
 Ago2 with endogenous insect cell RNA was predicted to cleave the bantam target, 
because bantam miRNA is present in insect cells. The lack of observed activity may have 
been due to a very small fraction of Ago2 carrying bantam, so little that it could not 
cleave enough target to be visible by autoradiography. Once bantam miRNA was 
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received, optimizing this reaction was not a priority. In the assay shown in Figure 8, 
target cleavage was achieved with pure Ago2 loaded with bantam. In an intermediate 
assay, both pure Ago2 and Ago2 with endogenous insect cell RNA were incubated with 
bantam. Presumably, bantam would have displaced some endogenous RNA from the 
preloaded Ago2. Results from this test were inconclusive because the reaction was loaded 
directly on to the denaturing urea gel without RNA extraction and much of the 
radioactivity signal remained in the well. To move ahead more quickly, RNA-free Ago2 
was loaded with bantam for the cleavage assay shown in Figure 8. This assay is the first 
in which Ago2’s slicer activity is observed, but only in the condition with a 1:5 ratio 
between target:Ago2/bantam. The absence of signal in the 1:1 ratio condition (lane 3) 
may be a result of error due to the numerous steps in the RNA extraction procedure, 
described in section 2.2.4. In the condition where cleavage appears successful, full length 
bantam is still the major species. These two results, the error and the low activity, should 







4.1 ARH3 activity 
 There are two results, discussed in section 3.1 and Figure 4, which raise 
interesting questions. First, when PARylated PARP-1 was treated with 5μg ARH3, the 
autoradiograph profile of the cleaved products was slightly different than when PARP-1 
was treated with PARGcat. It is possible that 5μg of ARH3 was not quite enough to 
achieve the same result, but it is also possible that the product it is leaving behind on the 
PARP-1 substrate are not the same terminal ADP-ribose moieties as PARGcat. Second, 
when PARP-1 was treated with 50μg ARH3, the autoradiograph signal disappeared 
completely. This could be explained several ways. ARH3 might have removed the 
terminal ADP-ribose attached to PARP-1, it may have cleaved the terminal ADP-ribose 
between the ribose and the phosphate groups, leaving a ribose moiety on the substrate or 
it could be that the radioactivity signal was too weak to scan. Both this and the previous 
result could be resolved with thin-layer chromatography (Kleine et al, 2008), in which 
any remaining ADP-ribose residues or chains were separated from PARP-1 and separated 
by size. ARH3 should also be tested for activity against linear PAR chains built by 
PARP-5a as opposed to the branched PAR chains built by PARP-1. 
 
4.2 PARP-5a expression 
 Difficulty in cloning PARP-5a into an insect cell expression vector stopped 
progress in that direction, but side-by-side cloning of the same gene into a human cell 
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expression vector succeeded. Because of the lab’s access to and expertise with human 
cell cultures, this would likely be the best next step to obtain PARP-5a. 
 
4.3 Argonaute2 ADP-ribosylation 
 If additional active PARP-12cat can be purified, it will allow the ability to test 
whether mono(ADP-ribosyl)ation has an effect on the cleavage activity of Ago2. 
Although PARP-5a does not appear able to PARylate Ago2 alone, results discussed in 
section 3.5 suggest that addition of PARP-13.2 could catalyze the reaction. Achieving 
this with PARP-13.2 in cell lysate is messy. Using purified PARP-13.2 would be ideal. 
Once Ago2 is subjected to modification, it would be optimal to enrich for PARylated 
Ago2. One way to do this would be to use biotinylated NAD+ so that the PAR chains 
could be captured by streptavidin attached to magnetic or agarose beads. These 
optimizations, along with those discussed in sections 3.4 and 3.5, should set up an assay 
that will clearly demonstrate whether mono or poly(ADP-ribosyl)ation modifies Ago2 
activity in vitro. If modification can be shown, it should be followed by PAR digestion 






Figure 2: ARH3 purification 
GST-ARH3 was expressed in E. coli, lysed and clarified. The soluble fraction was 
incubated with glutathione agarose beads. The SDS-PAGE scan on the left shows the first 
several steps of the purification: The beads were collected in an open gravity column, 
allowing unbound protein to flow through, then washed with lysis buffer. Thrombin was 
added to the bead slurry and incubated for 4 hours. Lysis buffer was used to washout 
ARH3 cleaved from the GST tag (labeled as elutions) in 5x1mL steps. These elutions 
were pooled, concentrated to 500μL and loaded on to an S200 size exclusion column 
controlled by an Äkta FPLC system. On the right is the S200 chromatogram, labeled in 
elution volume on the x-axis and absorbance units (at 280nm) on the y-axis. Fractions 
corresponding to three peaks were analyzed by SDS-PAGE, shown in an inset over the 
chromatogram. According to the column manufacturer, elution at 15mL corresponds to a 
protein of 35kDa. Peak 3 eluted at 15.68mL, indicating a protein slightly larger than 
35kDa, as expected for ARH3which is 39kDa. Fractions from peak 3 were pooled, 





Figure 3: PARP-12cat purification 
PARP-12cat was expressed in E. coli as a 6xHis fusion protein, lysed and clarified.  
A. PARP-12cat  was captured from the soluble fraction by nickel metal affinity 
chromatography. An enriched band is observed, indicated with an arrow, upon elution 
from the nickel column with 300mM imidazole. 
B. Due to the impurity of the first affinity capture, the elutions were pooled, dialyzed out 
of imidazole, reloaded onto the column and eluted with an imidazole step gradient. 
PARP-12cat eluted primarily at concentrations of 100mM and 150mM imidazole, 
indicated inside the box. These fractions were pooled. 
C. Proteins were precipitated from the previous elution by incremental addition of 
ammonium sulfate. Nearly all protein, including contaminants seen above and below 
PARP-12cat, precipitated together at 40% and 50% ammonium sulfate, the two rightmost 
lanes. These fractions were resuspended and pooled. 
D. Pooled protein was manually loaded onto an anion exchange column. The column 
flow-through and wash were collected. Protein was eluted from the column with a salt 
gradient by FPLC. PARP-12cat was observed in the wash and peak 1, but only the species 
in peak 1 showed activity when tested (see Fig. 4). The fractions indicated by the box 






Figure 4: Purified ARH3 is an active glycohydrolase 
PARP-1 was attached to magnetic nickel beads and allowed to auto-PARylate, activated 
by the presence of blunt-end double-stranded DNA. PAR chains were then digested with 
PARG or ARH3. Each reaction was run on SDS-PAGE, coomassie stained (left), then 
exposed to autoradiography (right, overlaid on coomassie). Input is 500ng PARP-1, 
followed by a bead-attachment control (Tmax, carried through each experimental step). 
PARylation is visualized using 32P-labeled ADP-ribose precursor NAD+ and appears as a 
smear on the autoradiograph due to variable-length PAR. Modification is also observed 
as a disappearance of PARP-1 in the coomassie stain. This is shown in T0 immediately 
after modification, and in the Tmax control, carried through further PAR digestion steps. 
When PARP-1 is treated with 5ng PARGcat, the PAR chain is digested, leaving only 
mono(ADP-ribose), visible as discrete bands on PARP-1 and its fragments in the 
autoradiograph. Treatment with ARH3 shows moderate PAR digestion at 0.5μg. With 
5μg ARH3, discrete bands are evident, although the pattern is different than those in the 
PARG condition. With 50μg ARH3, the autoradiograph signal is totally ablated. In the 
coomassie stain, PARP-1 is once again visible after treatment with both PARGcat and 
ARH3. This indicates the variable-length PAR chains are gone. In the rightmost lane, a 
band the size of ARH3 appears in the coomassie stain. Because the concentration of 
ARH3 was so high in this condition, some may have nonspecifically bound to the 










Figure 5: Purified PARP-12cat is an active mono(ADP-ribose) transferase 
A. PARP-12 catalytic domain was attached to magnetic nickel beads and allowed to 
automodify in the presence of 32P-labeled NAD+. PARP-1 is included for comparison. 
Two populations of PARP-12cat were tested for activity: one of which eluted from HiTrap 
Q anion exchange during the wash step, and another which eluted at a low NaCl 
concentration (elution). Reactions were run on SDS-PAGE, coomassie stained (left) then 
exposed to autoradiography (right, overlaid on coomassie). Included is a loading control 
of 500ng for PARP-1 and 1μg for each PARP-12cat species. Also included is an 
attachment lane to control for the amount of protein affixed to the beads. PARylation of 
PARP-1 is observed by a disappearance in the modification lane on the coomassie stain 
and a smear on the autoradiograph. In contrast, no disappearance is visible with PARP-
12cat modification, but a discrete band is visible upon autoradiography. The presence of a 
radioactive signal, but lack of mobility shift, is characteristic of mono(ADP-ribosyl)ation. 






Figure 6: Ago2 mono(ADP-ribosyl)ation by PARP-12cat  
Ago2 was attached to MagStrep beads and mixed with PARP-12cat in various molar 
ratios, and with 32P-lableled NAD+. The experimental conditions above lie under the 
horizontal line. In the first three conditions, Ago2 is constant at 1μg while the amount of 
PARP-12cat is varied. In the next three conditions, PARP-12cat is constant at 1μg while 
the amount of Ago2 is varied. In addition to the experimental conditions, radiolabeled 
NAD+ is included in the attachment control. The ADP-ribosylation activity of PARP-12cat 





Figure 7A: Ago2 poly(ADP-ribosyl)ation by PARP-5a 
TRF1 was attached to magnetic nickel beads; Ago2 was attached to MagStrep beads. 
Both were mixed with PARP-5a and various concentrations of NAD+. The overall 
concentration of non-radioactive NAD+ was varied, but the amount that was 32P-labeled 
was always 0.3μM. A band corresponding to TRF1 increases in strength on the 
autoradiograph as the concentration of NAD+ decreases, while only a faint band 








Figure 7B: Ago2 poly(ADP-ribosyl)ation by PARP-5a 
Ago2 was attached to MagStrep beads and mixed with PARP-5a alone or with one of 
several additions: lysate from 293F cells overexpressing GFP-PARP-13.2 or GFP only or 
total RNA from 293T cells. BSA was also tested with PARP-5a as a non-specific 
substrate. Compared with PARP-5a alone, all additives increased automodification 
activity. No autoradiograph signal corresponds to Ago2 or BSA when they were mixed 
with PARP-5a only. A signal may be visible corresponding to Ago2 when PARP-13.2 







Figure 8: Ago2-mediated RNA cleavage assay 
Wild-type bantam target RNA or a mutated target were 5’ 32P-phospholabeled. RNA-free 
Ago2 was loaded with bantam miRNA and mixed with the bantam target or the mutant 
target in two molar ratios. An RNase inhibitor, SUPERase In was used to prevent 
nonspecific cleavage in all conditions except (2), where a different inhibitor, RNase 
OUT, was tested. RNA from each reaction was isolated from protein and electrophoresed 
on a denaturing urea gel which was then exposed overnight to autoradiography for 
analysis. A 10-base pair DNA marker and an RNA 22-mer, both radiolabeled, were also 
run for size comparison. Reactions, from left to right: (1) WT target, (2) WT 
target:Ago2/bantam 1:1 with RNase OUT, (3) WT target:Ago2/bantam 1:1, (4) WT 
target:Ago2/bantam 1:5, (5) Mut. target, (6) Mut. target:Ago2/bantam 1:1, (7) Mut. 
target:Ago2/bantam 1:5. The expected size of the bantam target cleavage product is 20 
nucleotides. A band between the 20 base pair DNA marker and the RNA 22-mer appears 
in conditions 2 and 4, which is not visible in the control, 1. The lack of any signal in 
condition 3 is likely the result of error. As expected, this cleavage product is not visible in 
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